	US 12,213,961 B2
	Treatment of idiopathic pulmonary fibrosis
Carl-Johan Dalsgaard, Stockholm (SE); and Rohit Batta, Stockholm (SE)
Assigned to VICORE PHARMA AB, Stockholm (SE)
Filed by VICORE PHARMA AB, Stockholm (SE)
Filed on Nov. 17, 2023, as Appl. No. 18/513,181.
Application 18/513,181 is a continuation of application No. 17/680,654, filed on Feb. 25, 2022, granted, now 11,819,494.
Claims priority of application No. 2201723 (GB), filed on Feb. 10, 2022.
Prior Publication US 2024/0108604 A1, Apr. 4, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/4178 (2006.01); A61K 9/48 (2006.01); A61P 1/00 (2006.01); A61P 11/00 (2006.01)

CPC A61K 31/4178 (2013.01) [A61K 9/485 (2013.01); A61K 9/4858 (2013.01); A61P 1/00 (2018.01); A61P 11/00 (2018.01)]

27 Claims

1. A method of treating idiopathic pulmonary fibrosis in a patient having probable usual interstitial pneumonitis as determined by a pattern on an image of the patient's lungs, wherein said method comprises perorally administering to said patient a therapeutically-effective amount of a sodium salt of N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-iso-butyl-thiophene-2-sulfonamide, wherein said perorally administering is carried out after a minimum of two hours of fasting and fasting is continued for at least one hour after said perorally administering.